https://www.pharmaradar360.com/article/przed-uzenie-dodatkowego-swiadectwa-ochronnego-mog-oby-dziesieciokrotnie-zwieksz-d578bc7567a1bb55Pharma Surgeen2026-06-11T15:09:31.000ZPrzedłużenie dodatkowego świadectwa ochronnego mogłoby dziesięciokrotnie zwiększyć inwestycje w badania i rozwój w Europiehttps://www.pharmaradar360.com/article/regulation-of-medical-devices-in-northern-ireland-d5934f909d804c54Pharma Surgeen2026-06-11T14:22:09.000ZRegulation of medical devices in Northern Irelandhttps://www.pharmaradar360.com/article/clinical-research-career-pathways-survey-c5cb0f498f105b4aPharma Surgeen2026-06-11T13:24:55.000ZClinical Research Career Pathways Surveyhttps://www.pharmaradar360.com/article/0-2-2026-5f90624d30545e24Pharma Surgeen2026-06-11T12:46:26.000ZΔιακήρυξη υπ. Αριθ. 0/2/2026 Ηλεκτρονικού Ανοικτού κάτω των Ορίων Διαγωνισμού για την Προμήθεια μονάδων αποθήκευσης και υπηρεσιών μετάπτωσηςhttps://www.pharmaradar360.com/article/regulation-of-ai-in-healthcare-10f88174ca8f7445Pharma Surgeen2026-06-11T11:00:01.000ZRegulation of AI in Healthcarehttps://www.pharmaradar360.com/article/relmada-therapeutics-appoints-cns-drug-development-veteran-michael-quirk-as-seni-205d264caf7d86c9Pharma Surgeen2026-06-11T11:00:00.000ZRelmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Programhttps://www.pharmaradar360.com/article/research-national-commission-into-the-regulation-of-ai-in-healthcare-research-en-21bb1db32095ead8Pharma Surgeen2026-06-11T11:00:00.000ZResearch: National Commission into the Regulation of AI in Healthcare: research, engagement and call for evidence findingshttps://www.pharmaradar360.com/article/merck-animal-health-to-acquire-targan-2f6b4330db3ef43bPharma Surgeen2026-06-11T10:45:58.000ZMerck Animal Health to Acquire TARGANhttps://www.pharmaradar360.com/article/l-industrie-pharmaceutique-appelle-le-g7-a-investir-dans-l-innovation-pour-stimu-eae612766dc14463Pharma Surgeen2026-06-11T09:35:08.000ZL'industrie pharmaceutique appelle le G7 à investir dans l'innovation pour stimuler la compétitivité, la résilience et la croissancehttps://www.pharmaradar360.com/article/imuldosa-c-s-sol-in-130mg-26ml-5mg-ml-d387045970c061acPharma Surgeen2026-06-11T08:58:50.000ZΑνάκληση παρτίδων του φαρμακευτικού προϊόντος IMULDOSA C/S.SOL.IN 130MG/26ML (5MG/ML)https://www.pharmaradar360.com/article/medical-devices-ask-for-a-regulatory-advice-meeting-from-the-mhra-7c78aa5bda84204bPharma Surgeen2026-06-11T07:48:47.000ZMedical devices: ask for a regulatory advice meeting from the MHRAhttps://www.pharmaradar360.com/article/pharmaceutical-industry-calls-on-g7-to-invest-in-innovation-to-drive-competitive-5108affff37cb403Pharma Surgeen2026-06-11T06:55:15.000ZPharmaceutical industry calls on G7 to invest in innovation to drive competitiveness, resilience, and growthhttps://www.pharmaradar360.com/article/fda-grants-priority-review-for-roche-s-tecentriq-for-a-certain-type-of-stage-iii-93694650d74349fdPharma Surgeen2026-06-11T05:00:00.000ZFDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancerhttps://www.pharmaradar360.com/article/shinsa-list-of-approved-medical-devices-april-2004-to-september-2025-ac2f2ddaaf2000e9Pharma Surgeen2026-06-11T03:00:00.000Z[SHINSA]List of Approved Medical Devices: April 2004 to September 2025https://www.pharmaradar360.com/article/otsuka-foods-biwako-research-institute-develops-oishisa-lens-an-ai-system-that-p-fa2f8da3448e035dPharma Surgeen2026-06-11T00:00:00.000ZOtsuka Foods’ Biwako Research Institute Develops “Oishisa LENS,” an AI System That Predicts Flavor Profiles and Recipes to Secure Expertise Transfer and Enhance Product Design 58 Years After the Brand’s Launch, Preserving Bon Curry’s Signature Taste for the Next Generationhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-de63185ae8e7b009Pharma Surgeen2026-06-11T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-e93e0c3ff4089d73Pharma Surgeen2026-06-11T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-72fa36a0a4a4afb1Pharma Surgeen2026-06-11T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-e87ba35131f768b1Pharma Surgeen2026-06-11T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-04194922ceae2a3dPharma Surgeen2026-06-11T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-bee89148916908c6Pharma Surgeen2026-06-11T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-62f2f63c1b45fd06Pharma Surgeen2026-06-11T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-35298bc8ae37887fPharma Surgeen2026-06-11T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-d43ab4aaec3bc297Pharma Surgeen2026-06-11T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-4f343a4daa310fd2Pharma Surgeen2026-06-11T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-f2a24dfe04e8d07ePharma Surgeen2026-06-11T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-7c1bd4e5f3dc3bffPharma Surgeen2026-06-11T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-30345c83e11ff162Pharma Surgeen2026-06-11T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-eaaf54f94598bec1Pharma Surgeen2026-06-11T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/importance-of-blood-donations-during-summer-c8cdce3bb62cb2f3Pharma Surgeen2026-06-11T00:00:00.000ZImportance of Blood Donations During Summerhttps://www.pharmaradar360.com/article/acrp-fellow-encourages-flexibility-creativity-and-persistence-in-clinical-resear-d8c21a61db1638e9Pharma Surgeen2026-06-10T21:26:50.000ZACRP Fellow Encourages Flexibility, Creativity, and Persistence in Clinical Researchhttps://www.pharmaradar360.com/article/anmat-consolido-su-participacion-en-los-principales-espacios-internacionales-de-a6014d1a9ea04878Pharma Surgeen2026-06-10T18:26:07.000ZANMAT consolidó su participación en los principales espacios internacionales de regulación farmacéuticahttps://www.pharmaradar360.com/article/three-deals-in-six-days-everest-builds-late-stage-apac-portfolio-b6144bc862643edfPharma Surgeen2026-06-10T16:00:00.000ZThree deals in six days: Everest builds late-stage APAC portfoliohttps://www.pharmaradar360.com/article/3-fragen-an-unser-neues-boardmitglied-lauren-mcnamer-general-manager-von-lilly-s-dd58111caa29b7eaPharma Surgeen2026-06-10T15:17:39.000Z3 Fragen an unser neues Boardmitglied: Lauren McNamer, General Manager von Lilly Switzerlandhttps://www.pharmaradar360.com/article/zepbound-tirzepatide-and-shaquille-o-neal-launch-national-campaign-after-nba-leg-493743c6f37b4aacPharma Surgeen2026-06-10T13:30:00.000ZZepbound® (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatablehttps://www.pharmaradar360.com/article/celebrating-our-aspen-aspire-leadership-graduates-97af457c2334448aPharma Surgeen2026-06-10T13:20:53.000ZCelebrating our Aspen Aspire Leadership Graduateshttps://www.pharmaradar360.com/article/antengene-s-atg-201-gains-ind-clearance-in-china-a351e0b64f6dcca3Pharma Surgeen2026-06-10T13:00:00.000ZAntengene’s ATG-201 gains IND clearance in Chinahttps://www.pharmaradar360.com/article/allergan-aesthetics-releases-the-aesthetics-evolution-what-consumers-really-want-5a87b0ed5b11656cPharma Surgeen2026-06-10T12:00:00.000ZAllergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aestheticshttps://www.pharmaradar360.com/article/opportunities-for-patients-and-the-public-to-be-involved-in-the-work-of-the-mhra-8495d3dc8baed1e0Pharma Surgeen2026-06-10T11:26:08.000ZOpportunities for patients and the public to be involved in the work of the MHRAhttps://www.pharmaradar360.com/article/company-sellas-life-sciences-df8a2c2b7cd408acPharma Surgeen2026-06-10T10:31:56.000ZCompany - Sellas Life Scienceshttps://www.pharmaradar360.com/article/ibento-ibento-workshop-on-new-approach-methodologies-nams-held-following-iccr-20-4329d3d1643c3425Pharma Surgeen2026-06-10T03:00:00.000Z[IBENTO][IBENTO]Workshop on New Approach Methodologies (NAMs) Held following ICCR-20​https://www.pharmaradar360.com/article/update-on-patient-enrollment-in-phase-2-study-of-enzomenib-for-acute-leukemia-325c6873bf0725d8Pharma Surgeen2026-06-10T02:30:00.000ZUpdate on Patient Enrollment in Phase 2 Study of Enzomenib for Acute Leukemiahttps://www.pharmaradar360.com/article/how-summer-heat-can-impact-migraines-35cc0dc7e26973e7Pharma Surgeen2026-06-10T00:00:00.000ZHow Summer Heat Can Impact Migraineshttps://www.pharmaradar360.com/article/fda-approves-lilly-s-ebglyss-lebrikizumab-lbkz-for-one-maintenance-dose-every-ei-9d4fc7426a3911aaPharma Surgeen2026-06-09T22:18:00.000ZFDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitishttps://www.pharmaradar360.com/article/u-s-fda-accepts-takeda-sbla-for-review-in-pediatric-uc-and-crohn-s-disease-4216f81039e6b730Pharma Surgeen2026-06-09T20:30:12.000ZU.S. FDA Accepts Takeda sBLA for Review in Pediatric UC and Crohn’s Diseasehttps://www.pharmaradar360.com/article/jean-francois-brochard-elu-president-du-leem-et-composition-du-nouveau-bureau-801859f77000f7d7Pharma Surgeen2026-06-09T16:22:37.000ZJean-François Brochard élu Président du Leem et composition du nouveau Bureauhttps://www.pharmaradar360.com/article/acceso-pre-registro-asistencia-telematica-c80d4e46b0cbb943Pharma Surgeen2026-06-09T16:13:43.000ZAcceso Pre-registro Asistencia Telemáticahttps://www.pharmaradar360.com/article/innovent-submits-nda-for-cldn18-2-adc-for-gastric-cancer-daa68cf3c1501774Pharma Surgeen2026-06-09T16:00:00.000ZInnovent submits NDA for CLDN18.2 ADC for gastric cancerhttps://www.pharmaradar360.com/article/nmpa-gives-conditional-nods-to-drugs-by-lupeng-vcare-staidson-c88f64ff9fcc09b5Pharma Surgeen2026-06-09T16:00:00.000ZNMPA gives conditional nods to drugs by Lupeng, Vcare, Staidsonhttps://www.pharmaradar360.com/article/gsk-enters-agreement-to-acquire-nuvalent-inc-7d7b7e5faa37410fPharma Surgeen2026-06-09T12:00:00.000ZGSK enters agreement to acquire Nuvalent, Inc.https://www.pharmaradar360.com/article/promotional-material-national-ai-commission-ask-me-anything-bfe3aa0539014dd3Pharma Surgeen2026-06-09T11:31:32.000ZPromotional material: National AI Commission: Ask Me Anythinghttps://www.pharmaradar360.com/article/guidance-ai-airlock-simulation-workshops-62f59d59ddb2fd1bPharma Surgeen2026-06-09T10:41:05.000ZGuidance: AI Airlock Simulation Workshopshttps://www.pharmaradar360.com/article/guidance-ai-airlock-sandbox-phase-2-programme-report-e042e8b71b7377dePharma Surgeen2026-06-09T10:37:42.000ZGuidance: AI Airlock Sandbox Phase 2 Programme Reporthttps://www.pharmaradar360.com/article/31-6204144f8c50e3b7Pharma Surgeen2026-06-09T10:08:24.000ZΛΙΣΤΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΣΚΕΥΑΣΜΑΤΩΝ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΔΙΑΘΕΣΙΜΟΤΗΤΑΣ 31 ΜΑΪΟΥhttps://www.pharmaradar360.com/article/emrn-884157d5592502edPharma Surgeen2026-06-09T09:59:21.000Zο ΕΟΦ είναι μέλος του Ευρωπαϊκού Δικτύου Ρυθμιστικών Αρχών Φαρμάκων (EMRN)https://www.pharmaradar360.com/article/the-guidance-on-digital-and-decentralised-clinical-trials-dct-has-been-updated-cfc2b16fbc16b9d6Pharma Surgeen2026-06-09T07:46:00.000ZThe guidance on digital and decentralised clinical trials (DCT) has been updatedhttps://www.pharmaradar360.com/article/ra-committee-townhall-how-agentic-ai-is-redefining-regulatory-excellence-58e5f910a0ab273aPharma Surgeen2026-06-09T07:39:41.000ZRA Committee Townhall – How Agentic AI is Redefining Regulatory Excellencehttps://www.pharmaradar360.com/article/un-multi-stakeholder-hearing-on-pandemic-prevention-preparedness-and-response-pp-cb41d961f6a7a91cPharma Surgeen2026-06-09T06:00:08.000ZUN Multi-Stakeholder Hearing on Pandemic Prevention, Preparedness, and Response (PPPR)https://www.pharmaradar360.com/article/pharmac-to-fund-medicines-used-by-ambulance-providers-bfcb61eac3282003Pharma Surgeen2026-06-09T02:00:00.000ZPharmac to fund medicines used by ambulance providershttps://www.pharmaradar360.com/article/why-sleep-is-important-for-brain-health-74cb2281ea89d3b9Pharma Surgeen2026-06-09T00:00:00.000ZWhy Sleep Is Important for Brain Healthhttps://www.pharmaradar360.com/article/bausch-health-canada-inc-et-l-alliance-pancanadienne-pharmaceutique-concluent-av-f2f7997dc3e086bfPharma Surgeen2026-06-09T00:00:00.000ZBausch Health, Canada Inc. et l’Alliance pancanadienne pharmaceutique concluent avec succès leurs négociations, menant à la signature d’une lettre d’intention pour OKEDI MC (suspension injectable à libération prolongée de rispéridone) dans le traitement de la schizophréniehttps://www.pharmaradar360.com/article/bausch-health-canada-inc-and-the-pan-canadian-pharmaceutical-alliance-sign-lette-9e77384c46509b25Pharma Surgeen2026-06-09T00:00:00.000ZBausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of Pr OKEDI ® (Risperidone for extended-release injectable suspension) for the treatment of schizophreniahttps://www.pharmaradar360.com/article/gilead-and-merck-announce-positive-topline-results-from-two-phase-3-studies-eval-49971b9dd9fe51c3Pharma Surgeen2026-06-08T20:39:58.000ZGilead and Merck Announce Positive Topline Results from two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatmenthttps://www.pharmaradar360.com/article/merck-and-gilead-provide-update-on-phase-3-keynote-d46-evoke-03-study-2d8fc949202d0f77Pharma Surgeen2026-06-08T20:30:00.000ZMerck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Studyhttps://www.pharmaradar360.com/article/lilly-s-oral-glp-1-foundayo-orforglipron-delivered-superior-a1c-control-and-weig-8f0559512800821aPharma Surgeen2026-06-08T18:30:00.000ZLilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials